BIOA BioAge Labs, Inc.
Stock · NasdaqGS · United States · Healthcare · US09077V1008
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by BioAge Labs, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Mar 2027 17:00 | -0.68 | — | — | Upcoming |
| 05 Nov 2026 16:00 | -0.63 | -0.73 | -16.6% | Miss |
| 05 Aug 2026 16:00 | -0.62 | -0.58 | +7.1% | Beat |
| 08 May 2026 09:00 | -0.63 | -0.52 | +17.1% | Beat |
| 24 Mar 2026 09:00 | -0.67 | -0.72 | -7.7% | Miss |
| 06 Nov 2025 16:00 | -0.51 | -0.56 | -9.0% | Miss |
| 06 Aug 2025 16:00 | -0.38 | -0.60 | -57.3% | Miss |
| 06 May 2025 16:00 | -0.53 | -0.36 | +31.8% | Beat |
| 20 Mar 2025 17:00 | -0.66 | -1.75 | -167.8% | Miss |
| 07 Nov 2024 16:00 | -0.73 | -6.70 | -812.5% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 9M | — | -80.6M | -896.1% | -2.24 | +66.2% | -82.3M |
| 2024 | 0 | — | -71.1M | — | -6.63 | -108.9% | -51.9M |
| 2023 | 0 | — | -63.9M | — | -3.17 | +86.6% | -37.5M |
| 2022 | 0 | — | -39.7M | — | -23.76 | — | -36.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 23 Jan 2025 | 4.91 | 5.41 | 4.91 | 5.30 | +3.72% | 228,600 | |
| 22 Jan 2025 | 5.28 | 5.32 | 5.07 | 5.11 | -4.13% | 129,000 | |
| 21 Jan 2025 | 5.17 | 5.38 | 4.83 | 5.33 | +3.70% | 254,200 | |
| 17 Jan 2025 | 5.11 | 5.18 | 4.97 | 5.14 | +1.98% | 215,000 | |
| 16 Jan 2025 | 4.86 | 5.19 | 4.68 | 5.04 | +2.86% | 194,800 | |
| 15 Jan 2025 | 4.70 | 5.00 | 4.40 | 4.90 | +5.60% | 512,200 | |
| 14 Jan 2025 | 4.76 | 4.94 | 4.55 | 4.64 | -1.28% | 385,800 | |
| 13 Jan 2025 | 4.75 | 4.88 | 4.58 | 4.70 | -4.86% | 519,900 | |
| 10 Jan 2025 | 5.00 | 5.15 | 4.81 | 4.94 | -2.95% | 367,600 | |
| 08 Jan 2025 | 5.29 | 5.35 | 4.79 | 5.09 | -5.04% | 276,600 | |
| 07 Jan 2025 | 5.45 | 5.64 | 5.30 | 5.36 | -0.56% | 436,900 | |
| 06 Jan 2025 | 5.92 | 5.99 | 5.36 | 5.39 | -7.39% | 426,300 | |
| 03 Jan 2025 | 5.57 | 6.01 | 5.50 | 5.82 | +4.68% | 847,200 | |
| 02 Jan 2025 | 5.89 | 6.02 | 5.53 | 5.56 | -3.97% | 308,500 | |
| 31 Dec 2024 | 5.64 | 5.96 | 5.42 | 5.79 | +2.30% | 535,100 | |
| 30 Dec 2024 | 5.48 | 5.91 | 5.41 | 5.66 | +2.91% | 344,800 | |
| 27 Dec 2024 | 5.88 | 5.88 | 5.25 | 5.50 | -6.46% | 374,500 | |
| 26 Dec 2024 | 6.00 | 6.47 | 5.87 | 5.88 | -3.29% | 525,300 | |
| 24 Dec 2024 | 5.90 | 6.18 | 5.66 | 6.08 | +2.36% | 402,700 | |
| 23 Dec 2024 | 6.25 | 7.15 | 5.77 | 5.94 | -3.26% | 1,042,300 | |
| 20 Dec 2024 | 5.10 | 6.74 | 5.01 | 6.14 | +18.76% | 4,663,800 | |
| 19 Dec 2024 | 4.35 | 5.39 | 4.34 | 5.17 | +20.23% | 2,554,900 | |
| 18 Dec 2024 | 4.80 | 5.12 | 3.97 | 4.30 | +4.88% | 4,714,900 | |
| 17 Dec 2024 | 4.22 | 4.32 | 3.85 | 4.10 | -0.97% | 936,400 | |
| 16 Dec 2024 | 4.24 | 4.49 | 4.11 | 4.14 | -3.27% | 699,400 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
- BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates (opens in a new tab) 05 Nov 2026 21:30
- Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate (opens in a new tab) Benzinga · 05 Nov 2026 17:56
- Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline (opens in a new tab) Zacks · 29 Oct 2026 13:00
- BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says (opens in a new tab) MT Newswires · 12 Oct 2026 18:02
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 5.54 USD
- Market cap
- 245.4M
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -133.1× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -2.13× | Weak | 14.89× |
| Price / book | 0.71× | Good | 3.81× |
| Price / sales | 28.54× | Weak | 3.19× |
| EV / EBITDA | 0.3× | Good | 12.63× |
| Free cash flow yield | -27.5% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 58.6% |
| Operating margin | -12,554% | Weak | 7.8% |
| Net margin | 0% | Weak | 2.8% |
| Return on equity | -34.6% | Weak | 5.7% |
| Return on assets | -22.4% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.48× |
| Interest cover | -133.11× | Weak | 2.69× |
| Current ratio | 15.51× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BIOA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.